18 Mar Critical errors in clinical trial translation that can delay approval

Clinical trial translation has become a strategic part of European regulatory compliance. Since the full application of Regulation (EU) 536/2014 and centralised management through the Clinical Trials Information System (CTIS), consistency in documentation has become a matter of linguistic quality and regulatory risk. A term used inconsistently in the protocol and informed consent can trigger requests for clarification and delay a study’s authorisation.

A more transparent environment requires greater precision

The new European framework has increased the transparency and public visibility of clinical documentation. This implies that clinical trial translation must ensures scientific accuracy, terminological consistency, and clarity for the patient. Medical translation services work with glossaries approved by the sponsor and version control systems that ensure alignment between all the documents in the dossier. A medical translation agency with experience in clinical research understands that every terminological nuance can affect the ethical and scientific evaluation of the study.

Professional medical translation is not just about translating content between languages, but also understanding the regulatory context, the methodological logic of the trial, and the legal impact of the language used. When machine translation is used without expert review, the risk of inconsistencies increases, especially in endpoints, inclusion criteria, or descriptions of adverse events.

Medical translation as part of the quality system

Currently, clinical trial translation should be integrated into the quality system of the sponsor and CROs. It is not an add-on service, but a risk mitigation tool. Also, in decentralised studies, the integration of medical transcription processes into clinical interviews or monitoring meetings requires terminological consistency with the official documentation. A specialised medical translation agency allows traceability and consistency to be maintained in all documentation workflows.

It is important to remember that clinical trial translation is part of regulatory compliance and influences the sponsor’s reputation with European authorities.

FAQs

Is clinical trial translation mandatory in the EU?

Yes, especially documentation intended for patients and national authorities must be submitted in the corresponding official language.

Can machine translation be used in clinical documentation?

It can be helpful for internal tasks, but documentation that will be evaluated requires specialised medical translation.

What impact does CTIS have on translation?

It increases transparency and harmonisation, which raises the demand for documentary consistency.